Consistent with the LDL receptor paradigm,261 statin mevinolin (lovastatin) and anti‐PCSK9 monoclonal antibodies do not lower cholesterol in familial hypercholesterolaemia homozygotes.262, 263 In contrast, the anti‐PCSK9 monoclonal antibody combined with statins reduced the risk of cardiovascular diseases in LDL receptor–sufficient individuals.264. This evidence concerns the gene LDLR and cardiovascular disorder.